Developer docs
API playgroundTry for free, no card

Search company profiles

LeonaBio

Full company profile

uuid00q3l74

Namestring
LeonaBio
Legal namestring
LeonaBio, Inc.
Websiteurl
leonabio.com
Company typeenum
Public
Founded yearint
2019
Descriptiontext

LeonaBio is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington, developing novel small-molecule therapeutics for diseases with high unmet medical need. Its pipeline is anchored by two differentiated mechanisms: lasofoxifene, a selective estrogen receptor modulator (SERM) with a unique binding profile active against both wild-type and clinically significant ESR1-mutant estrogen receptors, currently in the registrational ELAINE-3 Phase 3 trial for ER+/HER2- metastatic breast cancer in combination with abemaciclib; and ATH-1105, an orally available, brain-penetrant positive modulator of the neurotrophic hepatocyte growth factor (HGF) system, with Phase 1 data demonstrating favorable safety, dose-proportional pharmacokinetics, and CNS penetration, and a Phase 2 proof-of-concept trial in ALS planned for the second half of 2026. Earlier-stage pipeline includes ATH-1020 (preclinical/Phase 1 complete in diabetic neuropathy) and fosgonimeton (previously evaluated in Alzheimer's/Parkinson's trials).

The company was originally founded as M3 Biotechnology, rebranded to Athira Pharma in 2019, and renamed LeonaBio, Inc. in January 2026 following the December 2025 acquisition of exclusive global development and commercialization rights to lasofoxifene from Sermonix Pharmaceuticals (excluding Asia and certain Middle Eastern countries). The transaction marked a deliberate strategic pivot from a pure neurodegeneration focus toward an oncology-led pipeline, supported by a $90 million private placement co-led by Commodore Capital, Perceptive Advisors, and TCGX that provides cash runway into 2028.

As a clinical-stage biotech, LeonaBio currently has no product revenue and no commercial pricing in place; future economics would come from FDA-approved drug commercialization through standard pharmaceutical and specialty-pharmacy channels, supplemented by potential licensing or partnership income for geographies excluded from the Sermonix agreement. The company engages its eventual physician audience (oncologists and neurologists) through medical-affairs channels, scientific publications in journals such as Annals of Oncology and Frontiers in Neurology, and participation in major medical meetings (AACR, BIO International Convention, ALS Drug Development Summit). Its institutional investor base is concentrated in life-sciences-specialist funds, with Perceptive Advisors also represented on the board following a May 2026 governance refresh.

Short descriptiontext

LeonaBio is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics, with lead Phase 3 program lasofoxifene for ESR1-mutant metastatic breast cancer and Phase 2-ready ATH-1105 for ALS, targeting oncology and neurodegenerative indications with high unmet need.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBothell, United States
HQ citystring
Bothell
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceuticals, small molecule therapeutics, oncology drug development, neurodegenerative disease therapeutics, metastatic breast cancer treatment
Industry2 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-stage Biopharmaceuticals / Oncology and Neurology Therapeutics
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Sales
TypeOne Time License
Description

As a clinical-stage biopharmaceutical company, LeonaBio currently has no product revenue. The company is developing lasofoxifene (Phase 3) for ER+/HER2-/ESR1-mutant metastatic breast cancer and ATH-1105 (Phase 2 planned) for ALS. Future revenue would come from commercializing FDA-approved drugs through standard pharmaceutical distribution channels.

biospace.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

LeonaBio is a late-clinical-stage biopharmaceutical company developing novel small molecule therapeutics for diseases with high unmet medical needs. Its lead asset, lasofoxifene, is a selective estrogen receptor modulator (SERM) in Phase 3 development for ER+/HER2-/ESR1-mutated metastatic breast cancer. Its second lead program, ATH-1105, is an orally available, brain-penetrant small molecule targeting the neurotrophic HGF system for ALS, with a Phase 2 proof-of-concept trial planned for H2 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Phase 3 data for lasofoxifene expected mid-2027
+4 more records
Product overview1 text field

LeonaBio is a late-clinical stage biopharmaceutical company developing novel small molecule therapeutics for diseases with high unmet medical needs. The company's lead drug candidates include lasofoxifene (a SERM in Phase 3 for ER+/HER2-/ESR1-mutated metastatic breast cancer) and ATH-1105 (a HGF positive modulator in Phase 2 planning for ALS). Additional pipeline candidates include ATH-1020 (diabetic neuropathy) and fosgonimeton (Alzheimer's/Parkinson's). The company also maintains early-stage compounds in preclinical discovery for neurodegenerative diseases.

Product and service4 records
1Lasofoxifene
CategoryOncology / Endocrine therapy
Description

A novel, nonsteroidal selective estrogen receptor modulator (SERM) with a unique binding profile designed to confer potent activity against both wild-type and mutant estrogen receptors, including clinically significant ESR1 mutations commonly associated with resistance to endocrine therapy in metastatic breast cancer. Currently in Phase 3 (ELAINE-3 trial) for ER+/HER2-/ESR1-mutated metastatic breast cancer in combination with abemaciclib after CDK4/6 inhibitor progression.

2ATH-1105
CategoryNeurology / Neurodegenerative disease therapeutics
Description

A novel, orally available, brain-penetrant, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS. Phase 2 proof-of-concept trial in ALS patients planned for H2 2026.

3ATH-1020
CategoryNeurology / Pain and neuropathy therapeutics
Description

A novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system. In preclinical models, ATH-1020 reduced measures of pain in models of diabetic neuropathy. Phase 1 completed; company to evaluate options for advancement.

4Fosgonimeton (ATH-1017)
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-04-21
Description

Independent researchers at VCU's Massey Comprehensive Cancer Center presented nonclinical data on lasofoxifene at AACR26 annual meeting, showing the drug protected against hormone withdrawal-induced bone loss while maintaining anti-tumor response in ER+ breast cancer models.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-01-09
Description

LeonaBio entered into an exclusive global license agreement (excluding Asia and certain Middle Eastern countries) with Sermonix Pharmaceuticals to develop and commercialize lasofoxifene, a Phase 3 SERM asset for metastatic breast cancer. LeonaBio paid approximately $34.9 million in equity plus monthly payments and up to $100 million in potential milestones.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing targeted protein degraders (PROTAC) including vepdegestrant in partnership with Pfizer for ER+/HER2- metastatic breast cancer, including ESR1-mutant populations. Overlapping breast cancer franchise targeting resistance mechanisms after endocrine therapy.

TypeBroad incumbent
Description

Major oncology incumbent developing giredestrant (oral SERD) for ER+/HER2- metastatic breast cancer including ESR1-mutant populations. Broad pharma with deep breast cancer franchise that competes directly with LeonaBio's target population and pricing environment.

TypeDirect peer
Description

Originating developer of lasofoxifene and direct licensor to LeonaBio (December 2025 exclusive global license excluding Asia/ME). Sermonix retains rights in excluded territories and continues SERD/SERM development in metastatic breast cancer, making it the most directly comparable peer.

TypeBroad incumbent
Description

Largest oncology incumbent in ER+/HER2- breast cancer via Verzenio (abemaciclib) — the very CDK4/6 inhibitor LeonaBio's ELAINE-3 combines lasofoxifene with. Broad incumbent with overlap in metastatic breast cancer but operates across many therapeutic areas.

TypeDirect peer
Description

Clinical-stage biotech developing neurotrophic factor-based therapies for peripheral neuropathy and ALS, with direct overlap to LeonaBio's HGF-MET approach. Comparable mechanism class targeting neuronal regeneration in neurodegenerative disease.

TypeBroad incumbent
Description

Large biopharmaceutical company with established ALS franchise (Spinraza, Qalsody) and broad neurodegenerative pipeline. Broader incumbent operating across multiple therapeutic areas, but its ALS neurology focus makes it a relevant competitive reference for ATH-1105's market entry.

TypeDirect peer
Description

Clinical-stage RNA-targeted biotech developing tofersen (Qalsody) for SOD1-mutant ALS, a leading approved ALS therapy. Comparable specialty biotech with CNS-penetrant mechanism for neurodegenerative disease, sharing patient enrollment challenges in ALS trials.

TypeDirect peer
Description

Late-clinical stage biotech developing tirasemtiv and reldesemtiv for ALS, with deep experience in ALS drug development. Directly comparable neuro-targeting biotech with similar clinical-stage risk profile and pipeline focus on motor neuron diseases.

TypeDirect peer
Description

Clinical-stage biotech developing ANAVEX 2-73 (blarcamesine) for Alzheimer's, Rett syndrome and other neurodegenerative diseases including ALS. Similar small molecule CNS-penetrant approach to treating neuro indications with high unmet need.

TypeDirect peer
Description

Clinical-stage oncology company developing targeted endocrine therapies for ER+/HER2- metastatic breast cancer, including ESR1-targeted candidates. Direct competitor to LeonaBio in the same patient population with a similar strategic focus on post-CDK4/6 resistance.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LeonaBio

Clinical-stage Biopharmaceuticals / Oncology and Neurology Therapeuticsleonabio.com

LeonaBio is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics, with lead Phase 3 program lasofoxifene for ESR1-mutant metastatic breast cancer and Phase 2-ready ATH-1105 for ALS, targeting oncology and neurodegenerative indications with high unmet need.

What LeonaBio does

LeonaBio is a clinical-stage biopharmaceutical company headquartered in Bothell, Washington, developing novel small-molecule therapeutics for diseases with high unmet medical need. Its pipeline is anchored by two differentiated mechanisms: lasofoxifene, a selective estrogen receptor modulator (SERM) with a unique binding profile active against both wild-type and clinically significant ESR1-mutant estrogen receptors, currently in the registrational ELAINE-3 Phase 3 trial for ER+/HER2- metastatic breast cancer in combination with abemaciclib; and ATH-1105, an orally available, brain-penetrant positive modulator of the neurotrophic hepatocyte growth factor (HGF) system, with Phase 1 data demonstrating favorable safety, dose-proportional pharmacokinetics, and CNS penetration, and a Phase 2 proof-of-concept trial in ALS planned for the second half of 2026. Earlier-stage pipeline includes ATH-1020 (preclinical/Phase 1 complete in diabetic neuropathy) and fosgonimeton (previously evaluated in Alzheimer's/Parkinson's trials).

The company was originally founded as M3 Biotechnology, rebranded to Athira Pharma in 2019, and renamed LeonaBio, Inc. in January 2026 following the December 2025 acquisition of exclusive global development and commercialization rights to lasofoxifene from Sermonix Pharmaceuticals (excluding Asia and certain Middle Eastern countries). The transaction marked a deliberate strategic pivot from a pure neurodegeneration focus toward an oncology-led pipeline, supported by a $90 million private placement co-led by Commodore Capital, Perceptive Advisors, and TCGX that provides cash runway into 2028.

As a clinical-stage biotech, LeonaBio currently has no product revenue and no commercial pricing in place; future economics would come from FDA-approved drug commercialization through standard pharmaceutical and specialty-pharmacy channels, supplemented by potential licensing or partnership income for geographies excluded from the Sermonix agreement. The company engages its eventual physician audience (oncologists and neurologists) through medical-affairs channels, scientific publications in journals such as Annals of Oncology and Frontiers in Neurology, and participation in major medical meetings (AACR, BIO International Convention, ALS Drug Development Summit). Its institutional investor base is concentrated in life-sciences-specialist funds, with Perceptive Advisors also represented on the board following a May 2026 governance refresh.

LeonaBio firmographics

Firmographics
Name
LeonaBio
Legal name
LeonaBio, Inc.
Website
https://leonabio.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
LeonaBio is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics, with lead Phase 3 program lasofoxifene for ESR1-mutant metastatic breast cancer and Phase 2-ready ATH-1105 for ALS, targeting oncology and neurodegenerative indications with high unmet need.
Ownership category
akta.pro rank

LeonaBio industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals / Oncology and Neurology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Clinical-stage biopharmaceuticals
  • Small molecule therapeutics
  • Oncology drug development
  • Neurodegenerative disease therapeutics
  • Metastatic breast cancer treatment

Where LeonaBio is headquartered

Location

Headquarters

HQ city
Bothell
HQ country
United States
HQ region
North America

Offices1 record

Markets served

LeonaBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Drug Sales: As a clinical-stage biopharmaceutical company, LeonaBio currently has no product revenue. The company is developing lasofoxifene (Phase 3) for ER+/HER2-/ESR1-mutant metastatic breast cancer and ATH-1105 (Phase 2 planned) for ALS. Future revenue would come from commercializing FDA-approved drugs through standard pharmaceutical distribution channels.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

LeonaBio product offering

Product offering

Core offering

LeonaBio is a late-clinical-stage biopharmaceutical company developing novel small molecule therapeutics for diseases with high unmet medical needs. Its lead asset, lasofoxifene, is a selective estrogen receptor modulator (SERM) in Phase 3 development for ER+/HER2-/ESR1-mutated metastatic breast cancer. Its second lead program, ATH-1105, is an orally available, brain-penetrant small molecule targeting the neurotrophic HGF system for ALS, with a Phase 2 proof-of-concept trial planned for H2 2026.

Product overview

LeonaBio is a late-clinical stage biopharmaceutical company developing novel small molecule therapeutics for diseases with high unmet medical needs. The company's lead drug candidates include lasofoxifene (a SERM in Phase 3 for ER+/HER2-/ESR1-mutated metastatic breast cancer) and ATH-1105 (a HGF positive modulator in Phase 2 planning for ALS). Additional pipeline candidates include ATH-1020 (diabetic neuropathy) and fosgonimeton (Alzheimer's/Parkinson's). The company also maintains early-stage compounds in preclinical discovery for neurodegenerative diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lasofoxifene A novel, nonsteroidal selective estrogen receptor modulator (SERM) with a unique binding profile designed to confer potent activity against both wild-type and mutant estrogen receptors, including clinically significant ESR1 mutations commonly associated with resistance to endocrine therapy in metastatic breast cancer. Currently in Phase 3 (ELAINE-3 trial) for ER+/HER2-/ESR1-mutated metastatic breast cancer in combination with abemaciclib after CDK4/6 inhibitor progression.
  • ATH-1105 A novel, orally available, brain-penetrant, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS. Phase 2 proof-of-concept trial in ALS patients planned for H2 2026.
  • ATH-1020 A novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system. In preclinical models, ATH-1020 reduced measures of pain in models of diabetic neuropathy. Phase 1 completed; company to evaluate options for advancement.
  • Fosgonimeton (ATH-1017)

Quantifiable outcome

  • Phase 3 data for lasofoxifene expected mid-2027
  • +4 more outcomes

Companies that use LeonaBio

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

LeonaBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

LeonaBio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered supporting and core.

  • Virginia Commonwealth University Massey Comprehensive Cancer CentersupportingStrategic or Co-development Partner · 21 April 2026Independent researchers at VCU's Massey Comprehensive Cancer Center presented nonclinical data on lasofoxifene at AACR26 annual meeting, showing the drug protected against hormone withdrawal-induced bone loss while maintaining anti-tumor response in ER+ breast cancer models.
  • Sermonix PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 9 January 2026LeonaBio entered into an exclusive global license agreement (excluding Asia and certain Middle Eastern countries) with Sermonix Pharmaceuticals to develop and commercialize lasofoxifene, a Phase 3 SERM asset for metastatic breast cancer. LeonaBio paid approximately $34.9 million in equity plus monthly payments and up to $100 million in potential milestones.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

LeonaBio competitors and assessment

Company assessment

Direct peers

  • Arvinas: Clinical-stage biotech developing targeted protein degraders (PROTAC) including vepdegestrant in partnership with Pfizer for ER+/HER2- metastatic breast cancer, including ESR1-mutant populations. Overlapping breast cancer franchise targeting resistance mechanisms after endocrine therapy.
  • Sermonix Pharmaceuticals: Originating developer of lasofoxifene and direct licensor to LeonaBio (December 2025 exclusive global license excluding Asia/ME). Sermonix retains rights in excluded territories and continues SERD/SERM development in metastatic breast cancer, making it the most directly comparable peer.
  • Helixmith: Clinical-stage biotech developing neurotrophic factor-based therapies for peripheral neuropathy and ALS, with direct overlap to LeonaBio's HGF-MET approach. Comparable mechanism class targeting neuronal regeneration in neurodegenerative disease.
  • Ionis Pharmaceuticals: Clinical-stage RNA-targeted biotech developing tofersen (Qalsody) for SOD1-mutant ALS, a leading approved ALS therapy. Comparable specialty biotech with CNS-penetrant mechanism for neurodegenerative disease, sharing patient enrollment challenges in ALS trials.
  • Cytokinetics: Late-clinical stage biotech developing tirasemtiv and reldesemtiv for ALS, with deep experience in ALS drug development. Directly comparable neuro-targeting biotech with similar clinical-stage risk profile and pipeline focus on motor neuron diseases.
  • Anavex Life Sciences: Clinical-stage biotech developing ANAVEX 2-73 (blarcamesine) for Alzheimer's, Rett syndrome and other neurodegenerative diseases including ALS. Similar small molecule CNS-penetrant approach to treating neuro indications with high unmet need.
  • Olema Oncology: Clinical-stage oncology company developing targeted endocrine therapies for ER+/HER2- metastatic breast cancer, including ESR1-targeted candidates. Direct competitor to LeonaBio in the same patient population with a similar strategic focus on post-CDK4/6 resistance.

Broad incumbents

  • Genentech (Roche): Major oncology incumbent developing giredestrant (oral SERD) for ER+/HER2- metastatic breast cancer including ESR1-mutant populations. Broad pharma with deep breast cancer franchise that competes directly with LeonaBio's target population and pricing environment.
  • Eli Lilly: Largest oncology incumbent in ER+/HER2- breast cancer via Verzenio (abemaciclib) — the very CDK4/6 inhibitor LeonaBio's ELAINE-3 combines lasofoxifene with. Broad incumbent with overlap in metastatic breast cancer but operates across many therapeutic areas.
  • Biogen: Large biopharmaceutical company with established ALS franchise (Spinraza, Qalsody) and broad neurodegenerative pipeline. Broader incumbent operating across multiple therapeutic areas, but its ALS neurology focus makes it a relevant competitive reference for ATH-1105's market entry.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

LeonaBio social profiles

Digital presence

LeonaBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LeonaBio leadership team

Management profile

Number of profiles

Profiles1 record

LeonaBio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LeonaBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LeonaBio

What does LeonaBio do?

LeonaBio is a late-clinical-stage biopharmaceutical company developing novel small molecule therapeutics for diseases with high unmet medical needs. Its lead asset, lasofoxifene, is a selective estrogen receptor modulator (SERM) in Phase 3 development for ER+/HER2-/ESR1-mutated metastatic breast cancer. Its second lead program, ATH-1105, is an orally available, brain-penetrant small molecule targeting the neurotrophic HGF system for ALS, with a Phase 2 proof-of-concept trial planned for H2 2026.

Is LeonaBio a public or private company?

LeonaBio is a public company. It is classified as public and is currently operating.

When was LeonaBio founded?

LeonaBio was founded in 2019. It employs 51 to 100 people.

Where is LeonaBio based?

LeonaBio is headquartered in Bothell, United States, in the North America region.

How does LeonaBio make money?

One revenue line is on record: pharmaceutical Drug Sales.

Who are LeonaBio's main competitors?

Direct peers on record are Arvinas, Sermonix Pharmaceuticals, Helixmith, Ionis Pharmaceuticals, Cytokinetics, Anavex Life Sciences and Olema Oncology. Broad incumbents are Genentech (Roche), Eli Lilly and Biogen.

Does LeonaBio have an API?

No public API is recorded for LeonaBio.

What industry is LeonaBio in?

LeonaBio's product category is Clinical-stage Biopharmaceuticals / Oncology and Neurology Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAIALAB, Lead Optimization & Preclinical Candidate Selection. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewMizuho maintains LeonaBio at Outperform, lowers price target to $12 from $13Mizuho maintained LeonaBio at Outperform and lowered its price target to $12 from $13, a 7.7% decrease. The price target implies an upside of 352.8% from the Nov 18 close of $2.65.TradingViewCitizens maintains LeonaBio at Market Outperform, lowers price target to $16 from $17Citizens maintained LeonaBio at Market Outperform and lowered its price target to $16 from $17, a 5.9% decrease. The target implies an upside of 395.4% from the Nov 16 close of $3.23.Investing.comCitizens cuts LeonaBio stock price target to $16 on valuationCitizens lowered its price target on LeonaBio to $16 from $17, maintaining an Outperform rating. The stock trades at $3.23, with trial enrollment on track to complete by Q4 2026. The firm expects Phase 3 top-line results in H2 2027.Investing.comLeonaBio at Cantor healthcare conference: bets on ESR1 combo edge By Investing.comLeonaBio presented its Phase III trial ELAINE-3 for lasofoxifene in ESR1-mutated metastatic breast cancer, with 500 of 600 patients enrolled. The company expects $146 million from warrant exercises and a cash runway to 2029. It aims to show a 3-month PFS benefit over fulvestrant plus abemaciclib.Pulse 2.0LeonaBio: ELAINE-3 Enrollment Reaches 495 Of About 600 Patients As Up To $146 Million Of Warrant Proceeds Could Support Upcoming MilestonesLeonaBio has enrolled 495 of approximately 600 patients in its Phase 3 ELAINE-3 trial for lasofoxifene, targeting completion by the fourth quarter of 2026 with topline data expected in late 2027. The company is advancing commercial readiness activities and holds up to $146 million in potential warrant proceeds from a December 2025 financing to support these milestones. LeonaBio acquired global rights to lasofoxifene (excluding Asia) from Sermonix Pharmaceuticals in December 2025.AdvfnLeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advancesLeonaBio reported a smaller-than-expected second-quarter loss of $0.80 per share while advancing its pivotal Phase 3 ELAINE-3 clinical trial for lasofoxifene, which is on schedule to complete patient enrollment in the fourth quarter of 2026. The company's net loss widened to $19.0 million due to increased research and development expenses associated with the trial, reducing its cash reserves to $51.1 million. Topline results from the study are expected in the second half of 2027.Investing.comCitizens lowers LeonaBio stock price target to $17 on valuation By Investing.comCitizens lowered its price target for LeonaBio stock to $17 from $18 while maintaining a Market Outperform rating, citing valuation concerns despite the company's positive pipeline progress. LeonaBio reported strong liquidity with over $50 million in cash and continues to advance its Phase 3 ELAINE-3 trial for breast cancer treatment. The adjustment reflects a risk-reduced discounted cash flow analysis, contrasting with the current trading price of $7.96 which remains below analyst consensus targets.Investing.comCitizens lowers LeonaBio stock price target to $17 on valuation By Investing.comCitizens lowered its price target for LeonaBio to $17 from $18 while maintaining a Market Outperform rating, citing valuation concerns despite the company's positive pipeline progress. LeonaBio continues to advance its Phase 3 ELAINE-3 trial and maintains strong liquidity with over $50 million in cash. The firm also highlighted recent analyst coverage and naming developments for its drug candidates.BioSpaceLeonaBio Reports Second Quarter 2026 Financial Results and Provides Business UpdateLeonaBio reported Q2 2026 financial results, with a net loss of $19.0 million and cash of $51.1 million. The company expects to complete enrollment of the Phase 3 ELAINE-3 trial for lasofoxifene in Q4 2026, with topline data expected in H2 2027. It also noted a $90 million private placement financing with warrants exercisable for up to $146 million.YahooLeonaBio Reports Second Quarter 2026 Financial Results and Provides Business UpdateLeonaBio, Inc. reported its financial results for the second quarter of 2026 and announced that it has enrolled 495 patients in its Phase 3 ELAINE-3 clinical trial for lasofoxifene. The company remains on track to complete enrollment by the fourth quarter of 2026, with topline data expected in the second half of 2027.